Neutralisation of circulating SARS-CoV-2 delta and omicron variants by convalescent plasma and SARS-CoV-2 hyperimmune intravenous human immunoglobulins for treatment of COVID-19
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2021.03.19.436183: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: This study was approved by the Food and Drug Administration’s Research Involving Human Subjects Committee (RIHSC #2020-04-02). Randomization not detected. Blinding The GFPDL affinity selection was performed in duplicate (two independent experiments by research fellow in the lab, who was blinded to sample identity). Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Lentivirus pseudovirion neutralization assay (PsVNA): Antibody preparations were evaluated by SARS-CoV-2 pseudovirus neutralization assay (PsVNA) using WA-1 strain, UK variant (B.1.1.7 with spike … SciScore for 10.1101/2021.03.19.436183: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: This study was approved by the Food and Drug Administration’s Research Involving Human Subjects Committee (RIHSC #2020-04-02). Randomization not detected. Blinding The GFPDL affinity selection was performed in duplicate (two independent experiments by research fellow in the lab, who was blinded to sample identity). Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Lentivirus pseudovirion neutralization assay (PsVNA): Antibody preparations were evaluated by SARS-CoV-2 pseudovirus neutralization assay (PsVNA) using WA-1 strain, UK variant (B.1.1.7 with spike mutations: H69-V70del, Y144del, N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H), SA variant (B.1.351 strain with spike mutations L18F, D80A, D215G, L242-244del, R246I, K417N, E484K, N501Y, D614G, and A701V), CA variant (B.1.429 strain with spike mutations S13I, W152C, L452R, D614G) and JP variant (P. S982Asuggested: NoneAffinity selection of SARS-CoV-2 GFPDL phages: Prior to panning of GFPDL with polyclonal hCoV-2IG antibodies, Ig components, which could non-specifically interact with phage proteins, were removed by incubation with UV-killed M13K07 phage-coated Petri dishes. hCoV-2IGsuggested: NoneExperimental Models: Cell Lines Sentences Resources The PsVNA using 293-ACE2-TMPRSS2 cell line was described previously (10, 11). 293-ACE2-TMPRSS2suggested: NonePseudovirions were produced by co-transfection Lenti-X 293T cells with psPAX2(gag/pol), pTrip-luc lentiviral vector and pcDNA 3.1 SARS-CoV-2-spike-deltaC19, using Lipofectamine 3000. 293Tsuggested: NoneThe supernatants were harvested at 48h post transfection and filtered through 0.45μm membranes and titrated using 293T-ACE2-TMPRSS2 cells (HEK293T cells that express ACE2 and TMPRSS2 proteins). 293T-ACE2-TMPRSS2suggested: NoneHEK293Tsuggested: NCBI_Iran Cat# C498, RRID:CVCL_0063)The virus-antibody mixture was then added to a 96-well plate with 5×104 Vero E6 cells. Vero E6suggested: RRID:CVCL_XD71)Software and Algorithms Sentences Resources The maximum resonance units (Max RU) data shown in the figures were the calculated RU signal for the 1 mg/mL hCoV-2IG sample or 2019-IVIG or 10-fold dilution of CP. Statistical Analysis: All experimental data were analyzed in GraphPad Prism, version 9.0.1 (GraphPad software Inc, San Diego, CA) or R package. GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)Correlation analysis of PRNT and PsVNA titers were performed by computing Pearson’s correlation coefficient in Graphpad. Graphpadsuggested: (GraphPad, RRID:SCR_000306)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-